Direct · single-molecule · real-time transcription kinetics

We screen the candidates that work — and flag the ones that don't.

RIFT resolves how a compound actually affects transcription — burst by burst, molecule by molecule — so cross-reactivity risk is built to surface on our bench, not in your trial.

For investors For biopharma & BD
Live transcription burst traceRIFT readout
Burst size · pausing duration · active promoters< 4 hrs
The problem

Most transcription factor drug candidates don't fail on efficacy. They fail because cross-reactivity shows up too late.

Across Phase 1–3, transcription factor and chromatin-targeted candidates fail at some of the highest rates in drug development — not for lack of efficacy, but because off-target and cross-reactivity effects go undetected until they surface in patients. Bulk biochemical assays average across millions of molecules and simply can't see it. By the time a compound reaches the clinic, that blind spot has already cost years and tens of millions of dollars.

RIFT is built to catch that risk on the bench — before it costs years and dollars in the clinic.

How RIFT sees what others can't

Four capabilities no other tool brings together.

Real-time In vitro Fluorescence Transcription — resolved molecule by molecule, not averaged from a population.

01

Native complex, intact

Cell-free, unlabeled, undisturbed.

02

Single-molecule resolution

Built to see the cross-reactivity that population averages erase.

03

Live kinetics

Burst size, pausing, active promoters, captured as they happen.

04

High throughput

Many compounds, run in parallel, at a fraction of the cost.

Delivered as a service

Send us compounds, get back a ranked shortlist.

No lab build-out required — RIFT runs as an outsourced screen.

01 · SUBMIT

Submit

Partners send their compounds.

02 · SCREEN

Screen

RIFT resolves each compound's effect on transcription, molecule by molecule.

03 · REPORT

Report

Ranked by efficacy + cross-reactivity risk.

04 · SUCCEED

Succeed

Advance the winners.

Our team

Industry scale-up experience, plus the inventor of RIFT.

RIFT was invented in the Taatjes Lab — Enlixa is a CU Boulder spinout, grown from that research.

Nik Chopra

Nik Chopra

Founder & CEO
  • Technology transfer, R&D to Ops — Natera & Guardant Health, moving molecular diagnostics from bench to commercial scale.
  • Assay development — developed and validated clinical-grade molecular assays across NIPT and liquid biopsy platforms.
  • Startups — early operator across 6 biotech startups, from pre-IPO diagnostics to early-stage therapeutics.
Dylan Taatjes, PhD

Dylan Taatjes, PhD

Founding Scientist
  • Transcription & chromatin biology — 20+ years at CU Boulder studying transcription regulation.
  • Inventor of RIFT — developed the single-molecule assay platform at the core of Enlixa's technology.
  • Research impact — 18,000+ citations, 70+ publications, 2 patents.
Get in touch

Ready to discuss your program?

Biopharma, BD, or investors — tell us a little and we'll be in touch.

Running a transcription factor or chromatin regulator program? Reach out.

Thanks — message sent.

We'll get back to you shortly.